FrancophonIA/ELRC3.0 huggingface dataset:
English: The point estimate of the hazard ratio (HR) was 0.461 (95 % confidence interval, 0.242 to 0.879) in the full population.
Maltese: Il-punt ta' stima tal-proporzjon ta' periklu (HR - hazard ratio) kien globalment (individwi kollha) 0.461 (95 % tal-intervall ta' kunfidenza, 0.242 sa 0.879) fil popolazzjoni sħiħa.
English: Prolactin levels were evaluated in all trials of all doses of aripiprazole (n = 28,242).
Maltese: Il-livelli ta' prolaktin kienu evalwati fil-provi kollha tad-dożi kollha ta' aripiprazole (n = 28,242).
English: Les Bouilides-Sophia Antipolis, 06560 Valbonne
Maltese: Elaiapharm2881 Route des Crêtes, Z.I. Les Bouilides-Sophia Antipolis, 06560 Valbonne
English: In three placebo-controlled trials (n = 938; mean age: 82.4 years; range: 56 to 99 years) of aripiprazole in elderly patients with psychosis associated with Alzheimer's disease, patients treated with aripiprazole were at increased risk of death compared to placebo.
Maltese: Fi tliet provi kontrollati minn plaċebo (n = 938; età medja: 82.4 snin; medda: 56 sa 99 sena) ta' aripiprazole f'pazjenti anzjani bil-psikosi assoċjat mal-marda Alzheimer, pazjenti kkurati b'aripirazole kellhom riskju ogħla ta' mewt imqabbla mal-plaċebo.
English: < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from the available data).
Maltese: (≥ 1/10), komuni (≥ 1/100 sa < 1/10), mhux komuni (≥ 1/1,000 sa < 1/100), rari (≥ 1/10,000 sa < 1/1,000), rari ħafna (< 1/10,000) u mhux magħruf (ma tistax tittieħed stima mid-data disponibbli).
English: Hepatitis Jaundice
Maltese: Epatite Suffejra
English: Indigo carmine aluminium lake (E 132)
Maltese: indigo karminju aluminju aħmar skur (E 132)
English: In the same trials, cerebrovascular adverse reactions (e.g. stroke, transient ischaemic attack), including fatalities, were reported in patients (mean age: 84 years; range: 78 to 88 years).
Maltese: Fl-istess provi, kienu rrapurtati reazzjonijiet avversi ċerebrovaskulari (eż. puplesija, attakk għaddieni iskemiku), inklużi uħud fatali, f'pazjenti (età medja: 84 sena; medda: 78 sa 88 sena).
English: In a 60- to 89-week, randomised, double-blind, placebo-controlled trial in adolescent subjects (n = 146; ages 13 to 17 years) with schizophrenia, there was a statistically significant difference in the rate of relapse of psychotic symptoms between the aripiprazole (19.39 %) and placebo (37.50 %) groups.
Maltese: Fi prova każwali, double-blind ta' minn 60 ġimgħa sa 89 ġimgħa, bi plaċebo bħala kontroll f'individwi adolexxenti (n = 146; etajiet ta' 13 sa 17-il sena) bi skiżofrenja, kien hemm differenza statistikament sinifikanti fir-rata ta' rkadar ta' sintomi psikotiċi bejn il-gruppi ta' aripiprazole (19.39 %) u plaċebo (37.50 %).
English: Oesophageal dysmotility and aspiration have been associated with the use of antipsychotics, including aripiprazole.
Maltese: Dismotilità tal-esofagu u aspirazzjoni ġew assoċjati mal-użu ta' antipsikotiċi, li jinkludi aripiprazole.
English: • The other ingredients are calcium silicate, croscarmellose sodium, crospovidone, silicon dioxide, xylitol, microcrystalline cellulose, aspartame, acesulfame potassium, vanilla flavour (contains lactose), tartaric acid and magnesium stearate.
Maltese: silicon dioxide, xylitol, microcrystalline cellulose, aspartame, acesulfame potassium, togħma ta' vanilla (fiha l-lactose), tartaric acid, magnesium stearate.
English: ABILIFY is effective in a dose range of 10 mg/day to 30 mg/day (i.e. 10 mL to 30 mL solution/day).
Maltese: 10 mg/jum sa 30 mg/jum (i.e. 10 mL sa 30 mL soluzzjoni/kuljum).
English: ABILIFY with food, drink and alcohol
Maltese: ABILIFY ma' ikel, xorb u alkoħol
English: • The other ingredients are disodium edetate, fructose, glycerin, lactic acid, methyl parahydroxybenzoate (E218), propylene glycol, propyl parahydroxybenzoate (E216), sodium hydroxide, sucrose, purified water, and orange flavour.
Maltese: • Is-sustanzi mhux attivi l-oħra huma disodium edetate, fructose, glycerin, lactic acid, methyl parahydroxybenzoate (E 218), propylene glycol, propyl parahydroxybenzoate (E 216), sodium hydroxide, sucrose, ilma ppurifikat, u togħma ta' larinġ.
English: • The other ingredients are lactose monohydrate, maize starch, microcrystalline cellulose, hydroxypropylcellulose and magnesium stearate.
Maltese: • Is-sustanzi mhux attivi l-oħra huma lactose monohydrate, maize starch, microcrystalline cellulose, hydroxypropyl cellulose, magnesium stearate.
English: This medicine will be given to you under medical supervision; it is therefore unlikely that you will be given too much.
Maltese: Din il-mediċina ser tingħatalek taħt superviżjoni medika; għalhekk huwa improbabbli li inti tingħata aktar milli suppost.
English: ABILIFY contains sodium
Maltese: ABILIFY fih sodium
English: Aripiprazole demonstrated statistically superior efficacy compared to placebo on the Aberrant Behaviour Checklist Irritability subscale.
Maltese: Aripiprazole wera effikaċja statistikament superjuri meta mqabbel mal-plaċebo fuq is sottoskala tal-Irritabilità tal-Lista tal-Iċċekkjar tal-Imġiba Aberranti.
English: This medicine contains 200 mg of fructose and 400 mg of sucrose in each mL.
Maltese: Din il-mediċina fih 200 mg ta' fructose u 400 mg ta' sucrose f'kull mL.
English: The observed mean improvement from baseline on the PANSS Excitement Component score at the primary 2-hour endpoint was 5.8 for placebo, 9.6 for lorazepam, and 8.7 for ABILIFY solution for injection.
Maltese: Excitement Component f'punt ta' tmiem primarju ta' sagħtejn kien 5.8 għal plaċebo, 9.6 għal lorazepam, u 8.7 għal soluzzjoni ta' ABILIFY għall-injezzjoni.
English: Patients were 7 to 17 years of age and presented an average score of 30 on Total Tic Score on the Yale Global Tic Severity Scale (TTS-YGTSS) at baseline.
Maltese: Il-pazjenti kienu bejn 7 snin sa 17-il sena u kienu ppreżentati b'punteġġ medju ta' 30 fit-Total Tic Score fil-Global Tic Severity Scale (TTS-YGTSS) fil-linja bażi.
English: Also contains sulfobutylether b-cyclodextrin, tartaric acid, sodium hydroxide, and water for injections.
Maltese: TA' EĊĊIPJENTI Għandu wkoll sulfobutylether b-cyclodextrin, tartaric acid, sodium hydroxide, u ilma għall injezzjonijiet.
English: ABILIFY 5 mg tablets ABILIFY 10 mg tablets ABILIFY 15 mg tablets ABILIFY 30 mg tablets aripiprazole
Maltese: ABILIFY 5 mg pilloli ABILIFY 10 mg pilloli ABILIFY 15 mg pilloli ABILIFY 30 mg pilloli aripiprazole
English: Adjunctive aripiprazole demonstrated superiority over placebo on the secondary outcome measure in Clinical Global Impression - Bipolar version (CGI-BP) Severity of Illness (SOI; mania) scores.
Maltese: Verżjoni bipolari (CGI-BP, Clinical Global Impression - Bipolar Version).
English: The singledose pharmacokinetics of aripiprazole was linear and dose-proportional.
Maltese: Il-farmakokinetiċi ta' doża unika ta' aripiprazole kienu lineari u proporzjonati mad-doża.
English: Excipient with known effect 186.54 mg lactose (as monohydrate) per tablet
Maltese: 186.54 mg lactose (bħala monohydrate) kull pillola
English: ABILIFY 5 mg tablets ABILIFY 10 mg tablets ABILIFY 15 mg tablets ABILIFY 30 mg tablets
Maltese: ABILIFY 5 mg pilloli ABILIFY 10 mg pilloli ABILIFY 15 mg pilloli ABILIFY 30 mg pilloli
English: ABILIFY contains lactose
Maltese: ABILIFY fih lactose
English: Schizophrenia with oral aripiprazole
Maltese: Skiżofrenja b'soluzzjoni aripiprazole orali
English: Magnesium stearate
Maltese: Tartaric acid Magnesium stearate
English: ABILIFY is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment (see section 5.1).
Maltese: ABILIFY hu indikat għal trattament ta' episodji manijaċi minn moderati sa severi f'Disturb Bipolari I u għall-prevenzjoni ta' episodju manijaku ġdid f'adulti li esperjenzaw episodji predominantament manijaċi u li l-episodji manijaċi tagħhom irrispondew għal trattament ta' aripiprazole (ara sezzjoni 5.1).
English: Outer carton: abilify 1 mg/mL
Maltese: ABILIFY 1 mg/mL
English: Kaplan-Meier relapse rates at week 16 were 35 % for aripiprazole and 52 % for placebo; the hazard ratio for relapse within 16 weeks (aripiprazole/placebo) was 0.57 (non-statistically significant difference).
Maltese: Ir-rati ta' rikaduta Kaplan-Meier f'ġimgħa 16 kienu ta' 35 % għal aripiprazole u ta' 52 % għal plaċebo; il-proporzjon ta' periklu ta' rikaduta fi żmien 16-il ġimgħa (aripiprazole/plaċebo) kien ta' 0.57 (differenza mhux statistikament sinifikanti).
English: Sudden death unexplained Torsades de pointes Ventricular arrhythmia Cardiac arrest Bradycardia
Maltese: Arritmiji ventrikulari Waqfien kardijaku Bradikardija
English: The AUC and Cmax of dehydroaripiprazole increased by 77 % and 43 %, respectively.
Maltese: L-AUC u Cmax ta' dehydro-aripiprazole żdiedu b' 77 % u 43 % rispettivament.
English: In the placebocontrolled trials, the mean weight gain was 0.4 kg for placebo and 1.6 kg for aripiprazole.
Maltese: Fil-provi kkontrollati bil-plaċebo, iż-żieda medja fil-piż kienet 0.4 kg għall-plaċebo u 1.6 kg għal aripiprazole.
English: extrapyramidal disorder (18.4 %), akathisia (16.0 %), and fatigue (11.8 %); and commonly (≥ 1/100, < 1/10) abdominal pain upper, heart rate increased, weight increased, increased appetite, muscle twitching, and dyskinesia.
Maltese: (18.4 %), akatisija (16 %), u għeja (11.8 %); u komuni (≥ 1/100, < 1/10) uġigħ fil-parti ta' fuq tal addome, żieda fir-rata ta' taħbit tal-qalb, żieda fil-piż, żieda fl-aptit, kontrazzjonijiet tal-muskoli, u diskinesija.
English: Manic episodes in Bipolar I Disorder: in a 12-week controlled trial, the incidence of EPS was 23.5 % for aripiprazole-treated patients and 53.3 % for haloperidol-treated patients.
Maltese: Episodji manijaċi f'Disturb Bipolari I: fi prova kkontrollata ta' 12-il ġimgħa, l-inċidenza ta' EPS kienet ta' 23.5 % għal pazjenti ttrattati b'aripiprazole u 53.3 % għal pazjenti ttrattati b'haloperidol.
English: ABILIFY 1 mg/mL oral solution aripiprazole
Maltese: ABILIFY 1 mg/mL soluzzjoni orali aripiprazole
English: Aripiprazole doses ranging from 0.5 mg to 30 mg administered once a day to healthy subjects for 2 weeks produced a dose-dependent reduction in the binding of 11C-raclopride, a D2/D3 receptor ligand, to the caudate and putamen detected by positron emission tomography.
Maltese: Dożi ta' aripiprazole li jvarjaw minn 0.5 mg sa 30 mg mogħtija darba kuljum għal ġimgħatejn lil nies b'saħħithom ipproduċew tnaqqis ta' dipendanza fuq id-droga fl-irbit ta' 11C-raclopride, reċettur li jgħaqqad D2/D3, caudate u l-putamen osservati bit-tomografija bl-emisssjoni positronika.
English: The AUC and Cmax of dehydro-aripiprazole, the active metabolite, decreased by 32 % and 47 %, respectively.
Maltese: L-AUC u Cmax ta' dehydro-aripiprazole, is-sustanza metabolika attiva, tnaqqsu bejn 32 % u 47 % rispettivament.
English: In another 12-week trial, the incidence of EPS was 26.6 % for patients treated with aripiprazole and 17.6 % for those treated with lithium.
Maltese: Fi prova oħra ta' 12-il ġimgħa, l-inċidenza ta' EPS kienet ta' 26.6 % għal pazjenti ttrattati b'aripiprazole u 17.6 % għal dawk ittrattati b'litju.
English: Rectangular and blue, engraved with "A-007" and "5" on one side.
Maltese: Rettangolari u blu, imnaqqxa b'“A-007” u “5” fuq naħa waħda.
English: The AUC and Cmax of dehydroaripiprazole, the active metabolite, decreased by 32 % and 47 %, respectively.
Maltese: L-AUC u Cmax ta' dehydroaripiprazole, is-sustanza metabolika attiva, tnaqqsu bejn 32 % u 47 % rispettivament.
English: • abdominal discomfort,
Maltese: • skumdità addominali,
English: Patients with attention deficit hyperactivity disorder (ADHD) comorbidity
Maltese: Pazjenti b'komorbidità ta' disturb tan-nuqqas ta' attenzjoni u ta' attività eċċessiva (ADHD, attention deficit hyperactivity disorder)
English: The Kaplan-Meier rates for recurrence to any mood episode for the adjunctive treatment arm were 16 % in aripiprazole + lithium and 18 % in aripiprazole + valproate compared to 45 % in placebo + lithium and 19 % in placebo + valproate.
Maltese: 18 % f'aripiprazole + valproate meta mqabbla ma' 45 % fi tal-plaċebo + lithium u 19 % fi tal-plaċebo + valproate.
English: In a haloperidol-controlled trial, the proportion of responder patients maintaining response to medicinal product at 52-weeks was similar in both groups (aripiprazole 77 % and haloperidol 73 %).
Maltese: Waqt prova kkontrollata b'haloperidol, il-proporzjon tal-pazjenti li irrispondew li żammew rispons għall-prodott mediċinali għall-52 ġimgħa kien simili fiż-żewġ gruppi (aripiprazole 77 % u haloperidol 73 %).
English: The incidence of hyperprolactinaemia or increased serum prolactin in patients treated with aripiprazole (0.3 %) was similar to that of placebo (0.2 %).
Maltese: L-inċidenza ta' iperprolaktinimija jew żieda ta' prolaktin fis-serum f'pazjenti trattati b'aripiprazole (0.3 %) kienet simili għal dik tal-plaċebo (0.2 %).
English: Aripiprazole exhibited high binding affinity in vitro for dopamine D2 and D3, serotonin 5-HT1A and 5-HT2A receptors and moderate affinity for dopamine D4, serotonin 5-HT2C and 5-HT7, alpha-1 adrenergic and histamine H1 receptors.
Maltese: Aripiprazole wera affinità ta' rabta qawwija in vitro għar-reċetturi tad-dopamina D2 u D3, tas-serotonina 5-HT1A u 5-HT2A, u b'mod inqas qawwi mar-reċetturi tad-dopamina D4, tas-serotonina 5-HT2C u 5-HT7, α1
English: ABILIFY 1 mg/mL oral solution
Maltese: ABILIFY 1 mg/mL soluzzjoni orali
English: ABILIFY 5 mg tablets are rectangular and blue, marked with ‘A-007' and ‘5' on one side.
Maltese: ABILIFY 5 mg pilloli huma rettangolari u ta' kulur blu bil-marka ‘A-007' u ‘5' fuq naħa waħda.
English: In a relative bioavailability study comparing the pharmacokinetics of 30 mg aripiprazole as the oral solution to 30 mg aripiprazole tablets in healthy subjects, the solution to the tablet ratio of geometric mean Cmax values was 122 % (n = 30).
Maltese: Fi studju ta' bijodisponibilità relattiva li tikkompara l-farmakokinetika ta' 30 mg ta' aripiprazole bħala soluzzjoni orali ma' 30 mg ta' pilloli aripiprazole f'suġġetti b'saħħithom, il-proporzjoni tas-soluzzjoni għall-pilloli tal-medja ġeometrika tal-valuri Cmax kien ta' 122 % (n = 30).
English: Date of first authorisation: 04 June 2004 Date of latest renewal: 04 June 2009
Maltese: Data tal-aħħar tiġdid: 04 ta' Ġunju 2009
English: PET-bottles with polypropylene child-resistant closure containing 50 mL, 150 mL or 480 mL per bottle.
Maltese: Flixken tal-PET b'tapp tal-polypropylene u li ma jinfetaħx mit-tfal li fih 50 mL, 150 mL or 480 mL kull flixkun.
English: ABILIFY is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.
Maltese: ABILIFY hu indikat għal trattament ta' skiżofrenja fl-adulti u fl-adolexxenti minn età ta' 15-il sena jew aktar.
English: EU/1/04/276/033 - 50 mL bottle EU/1/04/276/034 - 150 mL bottle EU/1/04/276/035 - 480 mL bottle
Maltese: EU/1/04/276/033 - flixkun ta' 50 mL EU/1/04/276/034 - flixkun ta' 150 mL EU/1/04/276/035 - flixkun ta' 480 mL
English: Elevations of CPK (Creatine Phosphokinase), generally transient and asymptomatic, were observed in 3.5 % of aripiprazole treated patients as compared to 2.0 % of patients who received placebo.
Maltese: Elevazzjonijiet ta' CPK (Kreatina Fosfokinejż), ġeneralment li tgħaddi u asintomatika, kienu osservati f'3.5 % tal-pazjenti ikkurati b'aripiprazole meta mqabbla ma' 2.0 % tal pazjenti li rċevew plaċebo.
English: These included: dose-dependent adrenocortical toxicity (lipofuscin pigment accumulation and/or parenchymal cell loss) in rats after 104 weeks at 20 mg/kg/day to 60 mg/kg/day (3 to 10 times the mean steady-state AUC at the maximum recommended human dose) and increased adrenocortical carcinomas and combined adrenocortical adenomas/carcinomas in female rats at 60 mg/kg/day (10 times the mean steady-state AUC at the maximum recommended human dose).
Maltese: Dawn jinkludu: tossiċità adreno-kortikali li tiddependi fuq id-doża (ġbir ta' kulur lipofuscin u/jew telf ta' ċelloli parenkimali) f'firien wara 104 ġimgħa fuq doża ta' 20 mg/kg/jum sa 60 mg/kg/jum (3 sa 10 darbiet aqwa mill-medja fi stat stabbli ta' l-AUC fl akbar doża rakkomandata għall-bnedmin) u żieda ta' tumuri adrenokortikali flimkien ma' adenomi taċ-ċelloli adrenokortikali/karċinomi fi ġrieden tas-sess femminili b'doża ta' 60 mg/kg/jum (10 darbiet ikbar mill-medja ta' l-AUC fi stat stabbli fid-doża massima rakkomandata fil-bnedmin).
English: In clinical studies, 10 mg/day to 30 mg/day doses of aripiprazole had no significant effect on the metabolism of substrates of CYP2D6 (dextromethorphan/3-methoxymorphinan ratio), CYP2C9 (warfarin), CYP2C19 (omeprazole), and CYP3A4 (dextromethorphan).
Maltese: Fi studji kliniċi, dożi t'aripiprazole ta' 10 mg/jum sa 30 mg/jum ma kellhom l-ebda effett ta' importanza fuq il-metaboliżmu tas-sustanzi li jaħdmu fuqhom is-CYP2D6 (dextromethorphan/3methoxymorphinan ratio), CYP2C9 (warfarin), CYP2C19 (omeprazole), u CYP3A4
English: In a 52-week, placebo-controlled trial, in patients with a current manic or mixed episode of Bipolar I Disorder who achieved sustained remission (Young Mania Rating Scale [YMRS] and MADRS with total scores ≤ 12) on aripiprazole (10 mg/day to 30 mg/day) adjunctive to lithium or valproate for 12 consecutive weeks, adjunctive aripiprazole demonstrated superiority over placebo with a 46 % decreased risk (hazard ratio of 0.54) in preventing bipolar recurrence and a 65 % decreased risk (hazard ratio of 0.35) in preventing recurrence into mania over adjunctive placebo but failed to demonstrate superiority over placebo in preventing recurrence into depression.
Maltese: Fi prova li damet sejra għal 52 ġimgħa, bil-plaċebo bħala kontroll, f'pazjenti li attwalment kellhom episodju manijaku jew episodju mħawwad ta' Disturb Bipolari I li kisbu fejqan sostnut (punteġġi totali ta' ≤ 12 għal Skala ta' Young għall-Klassifika tal-Manija [YMRS, Young Mania Rating Scale] u MADRS) b'aripiprazole (10 mg/kuljum sa 30 mg/kuljum) bħala mediċina addizzjonaliaġġuntiv malgħal lithiumju jew valproate għal 12-il ġimgħa konsekuttiva, l-għoti ta' aripiprazole bħala mediċina addizzjonaliaġġuntiv wera superjorità fuq il-plaċebo b'riskju mnaqqas ta' 46 % (proporzjon ta' periklu ta' 0.54) fil-prevenzjoni ta' sabiex ixejjen ir-rikorrenza bipolari u riskju mnaqqas ta' 65 % (proporzjon ta' periklu ta' 0.35) fil-prevenzjoni ta'sabiex ixejjen rikorrenza għal rikorrenza ta' manija meta mqabbel mal-plaċebo li ngħata bħala mediċina addizzjonali, aġġuntiv imma naqas li juri superjorità fuq il-plaċebo fil-prevenzjoni ta' biex ixejjen ir-rikorrenza għal dipressjoni.
English: In clinical studies, oral doses of 10 mg/day to 30 mg/day of aripiprazole had no significant effect on the metabolism of substrates of CYP2D6 (dextromethorphan/3-methoxymorphinan ratio), CYP2C9 (warfarin), CYP2C19 (omeprazole), and CYP3A4 (dextromethorphan).
Maltese: Fi studji kliniċi, dożi orali t'aripiprazole ta' 10 mg/jum sa 30 mg/jum ma kellhom l-ebda effett ta' importanza fuq il-metaboliżmu tas-sustanzi li jaħdmu fuqhom is-CYP2D6 (dextromethorphan/3methoxymorphinan ratio), CYP2C9 (warfarin), CYP2C19 (omeprazole), u CYP3A4
English: A vial provides 9.75 mg in 1.3 mL.
Maltese: Kunjett jagħti 9.75 mg f' 1.3 mL.
English: An additional finding was cholelithiasis as a consequence of precipitation of sulphate conjugates of hydroxy metabolites of aripiprazole in the bile of monkeys after repeated oral dosing at 25 mg/kg/day to 125 mg/kg/day (1 to 3 times the mean steady-state AUC at the maximum recommended clinical dose or 16 to 81 times the maximum recommended human dose based on mg/m2).
Maltese: Kien hemm ukoll każijiet ta' ġebla minħabba preċipitazzjoni tal-konjugi sulfatizzati tal-metaboliti idroġenizzati ta' aripiprazole fil-bile tax-xadini wara li ħadu ħafna dożi ta' 25 mg/kg/jum sa 125 mg/kg/jum mill-ħalq (1 sa 3 darbiet iktar mill-medja ta' l-AUC fi stat stabbli fid-doża massima rakkomandata fil-bnedmin jew 16 sa 81 darba iktar mid-doża massima rakkomandata fil-bniedem imkejla bħala mg/m2).
English: Aripiprazole is metabolised by multiple pathways involving the CYP2D6 and CYP3A4 enzymes but not CYP1A enzymes.
Maltese: Aripiprazole jiġi metabolizzat b'diversi sistemi li jirrikjedu l-enżimi CYP2D6 u CYP3A4 iżda mhux lenżimi CYP1A.
English: ABILIFY 30 mg tablets are round and pink, marked with ‘A-011' and ‘30' on one side.
Maltese: ABILIFY 30 mg pilloli huma tondi u ta' kulur roża bil-marka ‘A-011' u ‘30' fuq naħa waħda.
English: Contains aspartame and lactose.
Maltese: TA' EĊĊIPJENTI Għandu l-aspartame u lactose.
English: In placebo-controlled trials, the incidence of akathisia in bipolar patients was 12.1 % with aripiprazole and 3.2 % with placebo.
Maltese: Fi provi kkontrollati bi plaċebo, l-inċidenza ta' akatisja f'pazjenti bipolari kienet ta' 12.1 % b'aripiprazole u 3.2 % bi plaċebo.
English: Patients were 6 to 18 years and presented an average score of 29 on TTS-YGTSS at baseline.
Maltese: Il-pazjenti kienu minn 6 snin sa 18-il sena u ppreżentaw punteġġ medju ta' 29 fit-TTS-YGTSS fil-linja bażi.
English: ABILIFY contains the active substance aripiprazole and belongs to a group of medicines called antipsychotics.
Maltese: ABILIFY fih is-sustanza attiva aripiprazole u jappartjeni għal grupp ta' mediċini msejħa antipsikotiċi.
English: ABILIFY 7.5 mg/mL solution for injection aripiprazole
Maltese: ABILIFY 7.5 mg/mL soluzzjoni għall-injezzjoni aripiprazole
English: ABILIFY 10 mg tablets are rectangular and pink, marked with ‘A-008' and ‘10' on one side.
Maltese: ABILIFY 10 mg pilloli huma rettangolari u ta' kulur roża bil-marka ‘A-008' u ‘10' fuq naħa waħda.
English: • St John's Wort (Hypericum perforatum) used as a herbal remedy for mild depression
Maltese: • St John's Wort (Hypericum perforatum) użat bħala rimedju magħmul mill-ħxejjex għal depressjoni ħafifa
English: The effective dose range of ABILIFY solution for injection is 5.25 mg to 15 mg as a single injection.
Maltese: Il-medda effettiva ta' doża ta' soluzzjoni ABILIFY għall-injezzjoni hi 5.25 mg sa 15 mg bħala injezzjoni waħda.
English: ABILIFY 15 mg tablets Yellow iron oxide (E 172)
Maltese: ABILIFY 15 mg pilloli Iron oxide isfar (E 172)
English: ABILIFY is effective in a dose range of 10 mg/day to 30 mg/day.
Maltese: ABILIFY hu effettiv f'medda ta' dożi ta' 10 mg/kuljum sa 30 mg/kuljum.
English: Aripiprazole is widely distributed throughout the body with an apparent volume of distribution of 4.9 L/kg, indicating extensive extravascular distribution.
Maltese: Aripiprazole tiġi distribwita b'mod estensiv fil-ġisem, bil-volum medju ta' distribuzzjoni apparenti ta' 4.9 L/kg, li juri tqassim estensiv fis-sistema ekstravaskulari.
English: In the pooled trials, the incidence of low serum prolactin levels in females (< 3 ng/mL) and males (< 2 ng/mL) in aripiprazole-treated patients was 27/46 (58.7 %) and 258/298 (86.6 %), respectively.
Maltese: Fil-provi miġbura, l-inċidenza tal-livelli baxx ta' prolactin fis-serum fin-nisa (< 3 ng/mL) u fl-irġiel (< 2 ng/mL) f'pazjenti kkurati b'aripiprazole kienet 27/46 (58.7 %) u 258/298 (86.6 %), rispettivament.
English: In a 26-week, placebo-controlled trial in adult stabilised patients with chronic schizophrenia, oral aripiprazole had significantly greater reduction in relapse rate, 34 % in oral aripiprazole group and 57 % in placebo.
Maltese: aripiprazole orali kellu tnaqqis sinifikament akbar fir-rata ta' pazjenti li rkadew, 34 % fil-grupp ta' aripiprazole orali u 57 % fil-plaċebo.
English: ABILIFY 30 mg tablets:
Maltese: ABILIFY 30 mg pilloli:
English: Rectangular and pink, engraved with "A-008" and "10" on one side.
Maltese: Rettangolari u roża, imnaqqxa b'“A-008” u “10” fuq naħa waħda.
English: Other medicines and ABILIFY
Maltese: Mediċini oħra u ABILIFY
English: ABILIFY 30 mg tablets
Maltese: ABILIFY 30 mg pilloli
English: Compulsive shopping Poriomania
Maltese: Xiri kompulsiv Porjomanija Aggressjoni
English: Aspartame (E 951)
Maltese: Microcrystalline cellulose Aspartame (E 951) Acesulfame potassium
English: Photosensitivity reaction Alopecia
Maltese: Reazzjoni ta' sensittività għad-dawl Alopeċja